# Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico

> **NCT02345343** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 100 (estimated)

## Conditions studied

- Deep Vein Thrombosis
- Pulmonary Embolism

## Interventions

- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT02345343
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-04
- **Primary completion:** 2015-10-07
- **Final completion:** 2015-10-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2017-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02345343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02345343, "Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02345343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*